MD SB969

Requires insurers, nonprofit health service plans, and health maintenance organizations in Maryland to cover the full length of long-term antibiotic treatment (defined as oral, intramuscular, or intravenous antibiotics for longer than 4 weeks) for Lyme disease and related tick-borne illnesses when ordered by a licensed physician

Prohibits insurers from imposing quantitative limitations on long-term antibiotic treatment for these conditions

Prevents denial of coverage solely because treatment may be categorized as unproven, experimental, or investigational

Covers related tick-borne illnesses including bartonellosis, babesiosis, ehrlichiosis, anaplasmosis, and piroplasmosis

Applies to policies issued, delivered, or renewed on or after January 1, 2027